ERBB2 and breast cancer: Ocular AEs were not frequently reported with T-DXd in clinical studies of patients with HER2-positive breast cancer, including in DESTINY-Breast01 (N = 184), DESTINY-Breast03 (N = 257), and DESTINY-Breast04 (n = 371) (Table 2).30,32,33 Common ocular AEs across the 3 studies included dry eye (11.4%) and blurred vision (3.5%-4.9%), with one (0.5%) patient reporting grade 4 dry eye in DESTINY-Breast01.30–33 ORRs were favorable across the 3 studies, ranging from 52.3% to 79.7%.